person · Reporting owner
Sullivan Michael O'Keefe
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ORAGENICS INCOGEN · Entity 8495 | Chief Financial Officer | July 29, 2022 | August 02, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ORAGENICS INC
Report date July 29, 2022 · Filed August 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.36 · Expires 2032-07-29 | Direct | 200,000 |
Reported balance
After 2022-07-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-07-29 · Grant · Acquired 200,000 · Balance 200,000 F1: Represents an annual award of options to purchase shares of the Company's common stock under the Company's 2021 Equity Incentive Plan, that vest evenly in three tranches. One third of the options vest on the first anniversary of the grant date, the second third of the options vest on the second anniversary of the grant date and the final third vest on the third anniversary of the grant date. The option exercise price is the closing price on the date of the grant, July 29, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an annual award of options to purchase shares of the Company's common stock under the Company's 2021 Equity Incentive Plan, that vest evenly in three tranches. One third of the options vest on the first anniversary of the grant date, the second third of the options vest on the second anniversary of the grant date and the final third vest on the third anniversary of the grant date. The option exercise price is the closing price on the date of the grant, July 29, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2022 Filed Aug 2, 2022 20:38 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001493152-22-021018 · ownership.xml · derivative · entry 1 Sullivan Michael O'Keefe · CIK 0001542199 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-07-29 F1 · security: Represents an annual award of options to purchase shares of the Company's common stock under the Company's 2021 Equity Incentive Plan, that vest evenly in three tranches. One third of the options vest on the first anniversary of the grant date, the second third of the options vest on the second anniversary of the grant date and the final third vest on the third anniversary of the grant date. The option exercise price is the closing price on the date of the grant, July 29, 2022. F1 · shares: Represents an annual award of options to purchase shares of the Company's common stock under the Company's 2021 Equity Incentive Plan, that vest evenly in three tranches. One third of the options vest on the first anniversary of the grant date, the second third of the options vest on the second anniversary of the grant date and the final third vest on the third anniversary of the grant date. The option exercise price is the closing price on the date of the grant, July 29, 2022. F1 · derivative.exercise_date: Represents an annual award of options to purchase shares of the Company's common stock under the Company's 2021 Equity Incentive Plan, that vest evenly in three tranches. One third of the options vest on the first anniversary of the grant date, the second third of the options vest on the second anniversary of the grant date and the final third vest on the third anniversary of the grant date. The option exercise price is the closing price on the date of the grant, July 29, 2022. F1 · derivative.underlying_shares: Represents an annual award of options to purchase shares of the Company's common stock under the Company's 2021 Equity Incentive Plan, that vest evenly in three tranches. One third of the options vest on the first anniversary of the grant date, the second third of the options vest on the second anniversary of the grant date and the final third vest on the third anniversary of the grant date. The option exercise price is the closing price on the date of the grant, July 29, 2022. F1 · balance_after: Represents an annual award of options to purchase shares of the Company's common stock under the Company's 2021 Equity Incentive Plan, that vest evenly in three tranches. One third of the options vest on the first anniversary of the grant date, the second third of the options vest on the second anniversary of the grant date and the final third vest on the third anniversary of the grant date. The option exercise price is the closing price on the date of the grant, July 29, 2022. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 20:15 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantEmployee Stock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001493152-22-017711 · ownership.xml · derivative · entry 1 Sullivan Michael O'Keefe · CIK 0001542199 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2032-06-23 F1 · security: Represents an award of options to purchase shares of the Company's common stock under the Company's 2021 Equity Incentive Plan, in connection with interim service to the Company as Principal Executive Officer. The option vests immediately. The option exercise price is the closing price on the date of the grant, June 23, 2022. F1 · shares: Represents an award of options to purchase shares of the Company's common stock under the Company's 2021 Equity Incentive Plan, in connection with interim service to the Company as Principal Executive Officer. The option vests immediately. The option exercise price is the closing price on the date of the grant, June 23, 2022. F1 · balance_after: Represents an award of options to purchase shares of the Company's common stock under the Company's 2021 Equity Incentive Plan, in connection with interim service to the Company as Principal Executive Officer. The option vests immediately. The option exercise price is the closing price on the date of the grant, June 23, 2022. Read SEC document |
| March 29, 2022 Filed Mar 30, 2022 18:41 UTC | ORAGENICS INC OGEN · Entity 8495 | PurchaseCommon Stock | 20,000 | $0.35 | $6,922.00 |
DisclosureSEC source: 0001493152-22-008135 · ownership.xml · nonDerivative · entry 1 Sullivan Michael O'Keefe · CIK 0001542199 · Interim PEO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,255 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $0.3456 to $0.3469. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 22:13 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001493152-21-031897 · ownership.xml · derivative · entry 1 Sullivan Michael O'Keefe · CIK 0001542199 · Interim PEO, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-12-16 F1 · security: Represents an annual award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended that vest evenly in three tranches. One third of the options vest on the first anniversary of the grant date, the second third of the options vest on the second anniversary of the grant date and the final third vest on the third anniversary of the grant date. The option exercise price is the closing price on the date of the grant, December 16, 2021. F1 · shares: Represents an annual award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended that vest evenly in three tranches. One third of the options vest on the first anniversary of the grant date, the second third of the options vest on the second anniversary of the grant date and the final third vest on the third anniversary of the grant date. The option exercise price is the closing price on the date of the grant, December 16, 2021. F1 · derivative.exercise_date: Represents an annual award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended that vest evenly in three tranches. One third of the options vest on the first anniversary of the grant date, the second third of the options vest on the second anniversary of the grant date and the final third vest on the third anniversary of the grant date. The option exercise price is the closing price on the date of the grant, December 16, 2021. F1 · balance_after: Represents an annual award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended that vest evenly in three tranches. One third of the options vest on the first anniversary of the grant date, the second third of the options vest on the second anniversary of the grant date and the final third vest on the third anniversary of the grant date. The option exercise price is the closing price on the date of the grant, December 16, 2021. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:35 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantEmployee Stock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001493152-21-004424 · ownership.xml · derivative · entry 1 Sullivan Michael O'Keefe · CIK 0001542199 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-02-18 F1 · security: Represents an annual award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended that vest evenly in three tranches. One third of the options vest on the first anniversary of the grant date, the second third of the options vest on the second anniversary of the grant date and the final third vest on the third anniversary of the grant date. The option exercise price is the closing price on the date of the grant, February 18, 2021. F1 · shares: Represents an annual award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended that vest evenly in three tranches. One third of the options vest on the first anniversary of the grant date, the second third of the options vest on the second anniversary of the grant date and the final third vest on the third anniversary of the grant date. The option exercise price is the closing price on the date of the grant, February 18, 2021. F1 · derivative.exercise_date: Represents an annual award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended that vest evenly in three tranches. One third of the options vest on the first anniversary of the grant date, the second third of the options vest on the second anniversary of the grant date and the final third vest on the third anniversary of the grant date. The option exercise price is the closing price on the date of the grant, February 18, 2021. F1 · balance_after: Represents an annual award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended that vest evenly in three tranches. One third of the options vest on the first anniversary of the grant date, the second third of the options vest on the second anniversary of the grant date and the final third vest on the third anniversary of the grant date. The option exercise price is the closing price on the date of the grant, February 18, 2021. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:08 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantEmployee Stock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001493152-20-001768 · ownership.xml · derivative · entry 2 Sullivan Michael O'Keefe · CIK 0001542199 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2030-02-05 F2 · security: Represents a retention grant of award of options to purchase shares of the Company's common stock under the Company's Plan that vest evenly in three tranches. One third of the options vest on the first anniversary of the grant date, the second third of the options vest on the second anniversary of the grant date and the final third vest t on the third anniversary of the grant date. The option exercise price is the closing price on the date of the grant, February 5, 2020. F2 · shares: Represents a retention grant of award of options to purchase shares of the Company's common stock under the Company's Plan that vest evenly in three tranches. One third of the options vest on the first anniversary of the grant date, the second third of the options vest on the second anniversary of the grant date and the final third vest t on the third anniversary of the grant date. The option exercise price is the closing price on the date of the grant, February 5, 2020. F2 · derivative.exercise_date: Represents a retention grant of award of options to purchase shares of the Company's common stock under the Company's Plan that vest evenly in three tranches. One third of the options vest on the first anniversary of the grant date, the second third of the options vest on the second anniversary of the grant date and the final third vest t on the third anniversary of the grant date. The option exercise price is the closing price on the date of the grant, February 5, 2020. F2 · balance_after: Represents a retention grant of award of options to purchase shares of the Company's common stock under the Company's Plan that vest evenly in three tranches. One third of the options vest on the first anniversary of the grant date, the second third of the options vest on the second anniversary of the grant date and the final third vest t on the third anniversary of the grant date. The option exercise price is the closing price on the date of the grant, February 5, 2020. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:08 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantEmployee Stock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001493152-20-001768 · ownership.xml · derivative · entry 1 Sullivan Michael O'Keefe · CIK 0001542199 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2030-02-05 F1 · security: Represents an annual grant of award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended (the "Plan") that vests immediately. F1 · shares: Represents an annual grant of award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended (the "Plan") that vests immediately. F1 · derivative.exercise_date: Represents an annual grant of award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended (the "Plan") that vests immediately. F1 · balance_after: Represents an annual grant of award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended (the "Plan") that vests immediately. Read SEC document |
| September 27, 2018 Filed Oct 1, 2018 20:06 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantEmployee Stock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0000899243-18-025659 · doc4.xml · derivative · entry 1 Sullivan Michael O'Keefe · CIK 0001542199 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2028-09-27 F1 · security: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended that vest evenly in three tranches. One third of the options vest immediately, the second third of the options vest on the first anniversary of the grant date and the final third vest t on the second anniversary of the grant date. The option exercise price is the closing price on the date of the grant, September 27, 2018. F1 · shares: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended that vest evenly in three tranches. One third of the options vest immediately, the second third of the options vest on the first anniversary of the grant date and the final third vest t on the second anniversary of the grant date. The option exercise price is the closing price on the date of the grant, September 27, 2018. F1 · derivative.exercise_date: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended that vest evenly in three tranches. One third of the options vest immediately, the second third of the options vest on the first anniversary of the grant date and the final third vest t on the second anniversary of the grant date. The option exercise price is the closing price on the date of the grant, September 27, 2018. F1 · balance_after: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended that vest evenly in three tranches. One third of the options vest immediately, the second third of the options vest on the first anniversary of the grant date and the final third vest t on the second anniversary of the grant date. The option exercise price is the closing price on the date of the grant, September 27, 2018. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 20:19 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantEmployee Stock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0000899243-18-018137 · doc4.xml · derivative · entry 1 Sullivan Michael O'Keefe · CIK 0001542199 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2028-06-22 F1 · security: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, that vest on the first anniversary of the grant date. The option exercise price is the closing price on the date of the grant, June 22, 2018. F1 · shares: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, that vest on the first anniversary of the grant date. The option exercise price is the closing price on the date of the grant, June 22, 2018. F1 · balance_after: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, that vest on the first anniversary of the grant date. The option exercise price is the closing price on the date of the grant, June 22, 2018. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 19:30 UTC | ORAGENICS INC OGEN.BC · Entity 8495 | GrantEmployee Stock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0000899243-17-017200 · doc4.xml · derivative · entry 1 Sullivan Michael O'Keefe · CIK 0001542199 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2027-06-22 F1 · security: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, that vest equally over three years commencing on the first anniversary of the grant date. The option exercise price is the closing price on the date of the grant, June 22, 2017. F1 · shares: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, that vest equally over three years commencing on the first anniversary of the grant date. The option exercise price is the closing price on the date of the grant, June 22, 2017. F1 · balance_after: Represents an award of options to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, that vest equally over three years commencing on the first anniversary of the grant date. The option exercise price is the closing price on the date of the grant, June 22, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.